Growth Metrics

Merck (MRK) Cash from Operations Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 45.52%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -8.27%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -2.98%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 43.03%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.18%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 13.41%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 29.22%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -28.10%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 43.03%
Dec 31, 2025 -13.60%
Sep 30, 2025 11.77%
Jun 30, 2025 -8.52%
Mar 31, 2025 -19.32%
Dec 31, 2024 -12.19%
Sep 30, 2024 24.65%
Jun 30, 2024 41.49%
Mar 31, 2024 35.57%
Dec 31, 2023 -58.37%
Sep 30, 2023 69.60%
Jun 30, 2023 24.53%
Mar 31, 2023 23.72%
Dec 31, 2022 165.02%
Sep 30, 2022 9.85%
Jun 30, 2022 11.73%
Mar 31, 2022 52.74%
Dec 31, 2021 12.36%
Sep 30, 2021 19.76%
Jun 30, 2021 -16.20%
Mar 31, 2021 2.40%
Dec 31, 2020 -5.33%
Sep 30, 2020 49.64%
Jun 30, 2020 -16.69%
Mar 31, 2020 35.21%
Dec 31, 2019 -59.68%
Sep 30, 2019 12.46%
Jun 30, 2019 24.45%
Mar 31, 2019 -14.97%
Dec 31, 2018 -5.42%
Sep 30, 2018 -5.51%
Jun 30, 2018 7.84%
Mar 31, 2018 -20.33%
Dec 31, 2017 80.52%
Sep 30, 2017 -31.41%
Jun 30, 2017 12.74%
Mar 31, 2017 -50.52%
Dec 31, 2016 6.27%
Sep 30, 2016 -9.05%
Jun 30, 2016 -11.88%
Mar 31, 2016 -2.45%
Dec 31, 2015 32.90%
Sep 30, 2015 1.79%
Jun 30, 2015 -2.61%
Mar 31, 2015 1.97%
Dec 31, 2014 -32.38%
Sep 30, 2014 -1.70%
Jun 30, 2014 -6.72%
Mar 31, 2014 11.11%
Dec 31, 2013 -5.09%
Sep 30, 2013 15.07%
Jun 30, 2013 -11.08%
Mar 31, 2013 19.67%
Dec 31, 2012 -6.91%
Sep 30, 2012 129.31%
Jun 30, 2012 57.39%
Mar 31, 2012 44.59%